Pseudomonas aeruginosa as an Opportunistic Pathogen
暂无分享,去创建一个
[1] I. A. Holder,et al. Flagellar preparations from Pseudomonas aeruginosa: animal protection studies , 1982, Infection and immunity.
[2] T. Anderson,et al. Flagellar antibody stimulated opsonophagocytosis of Pseudomonas aeruginosa associated with response to either a- or b-type flagellar antigen. , 1989, Canadian journal of microbiology.
[3] T. Montie,et al. Flagella, motility and invasive virulence of Pseudomonas aeruginosa. , 1988, Journal of general microbiology.
[4] A. Kreger. Pathogenesis of Pseudomonas aeruginosa ocular diseases. , 1983, Reviews of Infectious Diseases.
[5] D. Teres,et al. Pneumonia in an intensive care unit. A 30-month experience. , 1974, Archives of internal medicine.
[6] C. Norden,et al. Experimental osteomyelitis caused by Pseudomonas aeruginosa. , 1980, The Journal of infectious diseases.
[7] R. Winchurch,et al. Prophylactic intravenous immunoglobulin replacement in high-risk burn patients. , 1987, The Journal of burn care & rehabilitation.
[8] J. Mcgowan,et al. PSEUDOMONAS AERUGINOSA PERITONITIS ASSOCIATED WITH CONTAMINATED POLOXAMER-IODINE SOLUTION , 1982, The Lancet.
[9] Hughes Jm. Epidemiology and prevention of nosocomial pneumonia. , 1988 .
[10] J. Skipper,et al. Pseudomonas osteochondritis complicating puncture wounds in children. , 1994, Journal of pediatric orthopedics.
[11] J. Posner,et al. CENTRAL NERVOUS SYSTEM INFECTIONS IN PATIENTS WITH CANCER , 1973, Medicine.
[12] A. Kropinski,et al. Heat shock response of Pseudomonas aeruginosa , 1988, Journal of bacteriology.
[13] M. Collins,et al. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. , 1984, The American journal of medicine.
[14] M. Tong. Septic complications of war wounds. , 1972, JAMA.
[15] B. Piraino,et al. A five-year study of the microbiologic results of exit site infections and peritonitis in continuous ambulatory peritoneal dialysis. , 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] G. P. Kerby. Pseudomonas aeruginosa bacteremia; summary of literature, with report of a case. , 1947, American journal of diseases of children.
[17] H. Chapel,et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. , 1989, Blood.
[18] E. Jawetz,et al. Infections of the central nervous system due to pseudomonas aeruginosa. , 1969, Journal of neurosurgery.
[19] R. Douglas,et al. Malignant external otitis: a severe form of otitis in diabetic patients. , 1976, The American journal of medicine.
[20] Y. Masuho,et al. Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa. , 1985, The Journal of infectious diseases.
[21] M. Glauser,et al. Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5. , 1987, The Journal of infectious diseases.
[22] P. Carbone,et al. Pseudomonas pneumonia. A retrospective study of 36 cases. , 1973, The American journal of medicine.
[23] J. Gatell,et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. , 1988, Reviews of infectious diseases.
[24] R. Bland,et al. Otitis media in the first six weeks of life: diagnosis, bacteriology, and management. , 1972, Pediatrics.
[25] W. Steinmüller,et al. Pharmacokinetics of anti-Pseudomonas hyperimmunoglobulin after single intravenous administration in healthy subjects , 1989 .
[26] N. Sigal,et al. Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa , 1988, Infection and immunity.
[27] A. Fanaroff,et al. Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study. , 1989, The Journal of pediatrics.
[28] D. Armstrong,et al. Bacteremia and fungemia in patients with neoplastic disease. , 1987, The American journal of medicine.
[29] S. Pitlik,et al. Ecthyma gangrenosum without bacteremia. Report of six cases and review of the literature. , 1987, Archives of internal medicine.
[30] R. Quintiliani,et al. Bacteremic Pseudomonas pneumonia. , 1974, JAMA.
[31] P. Schmitz,et al. The influence of immunoglobulin on the development of Pseudomonas aeruginosa infection in an immunocompromised mouse model. , 1985, Journal of biological standardization.
[32] M. Collins,et al. Comparative anti-Pseudomonas aeruginosa activity of chemically modified and native immunoglobulin G (human), and potentiation of antibiotic protection against Pseudomonas aeruginosa and group B Streptococcus in vivo. , 1984, The American journal of medicine.
[33] C. Kallick,et al. Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago. , 1985, The Journal of infectious diseases.
[34] D. Kemeny,et al. IgG subclass antibody production in human serum sickness. , 1990, The Journal of allergy and clinical immunology.
[35] R. Hodges,et al. Inhibition of pilus-mediated adhesion of Pseudomonas aeruginosa to human buccal epithelial cells by monoclonal antibodies directed against pili , 1990, Infection and immunity.
[36] J. Nadol,et al. Invasive external otitis. Report of 21 cases and review of the literature. , 1981, The American journal of medicine.
[37] A. Neely,et al. Plasma proteolytic activity following burns. , 1988, The Journal of trauma.
[38] N. Sigal,et al. A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia. , 1990, The Journal of infectious diseases.
[39] T. Montie,et al. Protection against Pseudomonas aeruginosa infection by passive transfer of anti-flagellar serum. , 1987, Canadian journal of microbiology.
[40] M. McPherson,et al. The molecular and biochemical basis of cystic fibrosis , 1987, Bioscience reports.
[41] D. Thornton,et al. Mucinophilic and chemotactic properties of Pseudomonas aeruginosa in relation to pulmonary colonization in cystic fibrosis , 1990, Infection and immunity.
[42] V. Yu,et al. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. , 1988, The American journal of medicine.
[43] H. Ceri,et al. Immunochemical examination of the Pseudomonas aeruginosa glycocalyx: a monoclonal antibody which recognizes L-guluronic acid residues of alginic acid. , 1985, Canadian journal of microbiology.
[44] M. Lederman,et al. Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. , 1987, The American review of respiratory disease.
[45] J. McCutchan,et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1983, The New England journal of medicine.
[46] Y. Masuho,et al. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. , 1984, The Journal of infectious diseases.
[47] J. Pennington,et al. Influence of genetic factors on natural resistance of mice to Pseudomonas aeruginosa. , 1979, The Journal of infectious diseases.
[48] I. Fong,et al. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. , 1985, Reviews of infectious diseases.
[49] A. Nowotny,et al. Relationship of structure to function in bacterial endotoxins: serologically cross-reactive components and their effect on protection of mice against some gram-negative infections. , 1976, Journal of general microbiology.
[50] R. Ansorg. [Flagella specific H antigenic schema of Pseudomonas aeruginosa (author's transl)]. , 1978, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie.
[51] R. Ramphal,et al. Evidence for the in vivo degradation of human respiratory mucins during Pseudomonas aeruginosa infection. , 1989, Biochimica et biophysica acta.
[52] James R. Chandler. Malignant external otitis , 1968, The Laryngoscope.
[53] A. Plebani,et al. Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates. , 1987, The Journal of pediatrics.
[54] P. Edmonds,et al. Epidemiology of pseudomonas aeruginosa in a burn hospital: evaluation of serological, bacteriophage, and pyocin typing methods. , 1972, Applied microbiology.
[55] H. Levison,et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. , 1985, The American journal of medicine.
[56] J. Pennington,et al. Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host. , 1987, The Journal of infectious diseases.
[57] L. S. Young,et al. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide , 1986, Infection and immunity.
[58] Y. Masuho,et al. A new common polysaccharide antigen of strains of Pseudomonas aeruginosa detected with a monoclonal antibody. , 1985, The Journal of infectious diseases.
[59] R. Klein,et al. Wound Infection During the Yom Kippur War; Observations Concerning Antibiotic Prophylaxis and Therapy , 1975, Annals of surgery.
[60] M. Collins,et al. Anti-Pseudomonas aeruginosa activity of an intravenous human IgG preparation in burned mice. , 1983, The Journal of trauma.
[61] J. Naglich,et al. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa. Treatment with intravenous immune globulin. , 1984, The American journal of medicine.
[62] B. Chabner,et al. Pseudomonas blepharoconjunctivitis: a complication of combination chemotherapy. , 1974, Archives of ophthalmology.
[63] M. Pollack,et al. Exotoxin production by clinical isolates of pseudomonas aeruginosa , 1977, Infection and immunity.
[64] M. Campa,et al. Role of specific delayed-type hypersensitivity in Pseudomonas aeruginosa-infected mice. , 1982, Immunology.
[65] D. R. Barry,et al. Postoperative infection with Pseudomonas aeruginosa in an eye hospital. , 1966, Lancet.
[66] C. Feit,et al. The presence of viral particles in hybridoma clones secreting monoclonal antibodies. , 1982, The New England journal of medicine.
[67] P. Gallagher,et al. Pseudomonas bacteremia in a community teaching hospital, 1980-1984. , 1989, Reviews of infectious diseases.
[68] A. Arbulu,et al. Consequences of total tricuspid valvulectomy without prosthetic replacement in treatment of Pseudomonas endocarditis. , 1974, The Journal of thoracic and cardiovascular surgery.
[69] N. Sigal,et al. X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa , 1988, Infection and immunity.
[70] H. Hill,et al. Comparative opsonic activity of intravenous gamma globulin preparations for common bacterial pathogens. , 1984, The American journal of medicine.
[71] J. Alexander,et al. Clinical evaluation of Pseudomonas hyperimmune globulin. , 1973, The Journal of surgical research.
[72] T. Kawamura,et al. Occurrence of D-rhamnan as the common antigen reactive against monoclonal antibody E87 in Pseudomonas aeruginosa IFO 3080 and other strains , 1990, Journal of bacteriology.
[73] W. Shellow,et al. Green striped nails: chromonychia due to Pseudomonas aeruginosa. , 1968, Archives of Dermatology.
[74] A. Mason,et al. Current approach to prevention and treatment of Pseudomonas aeruginosa infections in burned patients. , 1983, Reviews of infectious diseases.
[75] P. Liu,et al. Three new major somatic antigens of Pseudomonas aeruginosa , 1990, Journal of clinical microbiology.
[76] K. Murakami,et al. Monoclonal antibodies against species-specific cephalosporinase of Pseudomonas aeruginosa. , 1985, European journal of biochemistry.
[77] P. Liu,et al. Exotoxins of Pseudomonas aeruginosa. II. Concentration, purification, and characterization of exotoxin A. , 1973, The Journal of infectious diseases.
[78] M. Collins,et al. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa. , 1990, FEMS microbiology immunology.
[79] C. Kallick,et al. Recovery of Pseudomonas aeruginosa from syringes of drug addicts with endocarditis. , 1981, The Journal of infectious diseases.
[80] P. Edmonds,et al. Epidemiology of Pseudomonas aeruginosa in a Burns Hospital: Surveillance by a Combined Typing System , 1972, Applied microbiology.
[81] E. McGroarty,et al. Analysis of a common-antigen lipopolysaccharide from Pseudomonas aeruginosa , 1989, Journal of bacteriology.
[82] D. Woods,et al. Monoclonal antibodies to Pseudomonas aeruginosa ferripyochelin-binding protein , 1986, Infection and immunity.
[83] M. Vasil,et al. Incidence of exotoxin production by Pseudomonas species , 1977, Infection and immunity.
[84] M. Heckman,et al. Pseudomonas aeruginosa pneumonia in adults. , 1973, The American review of respiratory disease.
[85] V. Yu,et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. , 1989, The American journal of medicine.
[86] D. Dunn,et al. Treatment of experimental gram-negative bacterial sepsis with murine monoclonal antibodies directed against lipopolysaccharide. , 1989, Surgery.
[87] H. Noguchi,et al. Heterogeneity of the L-rhamnose residue in the outer core of Pseudomonas aeruginosa lipopolysaccharide, characterized by using human monoclonal antibodies , 1989, Infection and immunity.
[88] L. Cluff,et al. Pseudomonas bacteremia. Review of 108 cases. , 1976, The American journal of medicine.
[89] L. Corbeil,et al. Cross-reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous gram-negative bacteria and extracted lipopolysaccharides. , 1989, The Journal of infectious diseases.
[90] M. Thomassen,et al. Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition , 1985, Infection and immunity.
[91] W. R. Mccabe,et al. Meningitis caused by gram-negative bacilli. , 1980, Annals of internal medicine.
[92] J. Pennington,et al. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis , 1990, Pediatric pulmonology.
[93] G. D. Thomas,et al. Nosocomial respiratory infections with gram-negative bacilli. The significance of colonization of the respiratory tract. , 1972, Annals of internal medicine.
[94] G. Pier,et al. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide , 1989, Infection and immunity.
[95] J. McCutchan,et al. Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum. , 1975, Transactions of the Association of American Physicians.
[96] S. Davis,et al. Efficacy of modified human immune serum globulin in the treatment of experimental murine infections with seven immunotypes of Pseudomonas aeruginosa. , 1975, The Journal of infectious diseases.
[97] R. Lynn,et al. Pseudomonal and candidal peritonitis as a complication of continuous ambulatory peritoneal dialysis in human immunodeficiency virus-infected patients. , 1989, The American journal of medicine.
[98] H. Jacot-Guillarmod. Human Monoclonal Antibodies , 1990 .
[99] L. Saravolatz,et al. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients. , 1991, The Journal of infectious diseases.
[100] B. Greenbaum. Differences in Immunoglobulin Preparations for Intravenous Use: A Comparison of Six Products , 1990, The American journal of pediatric hematology/oncology.
[101] E. Honda,et al. Effects of the common protective antigen (OEP) and toxoids of protease and elastase from Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink. , 1977, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie.
[102] W. Su,et al. Ecthyma gangrenosum: report of clinical, histopathologic, and bacteriologic aspects of eight cases. , 1984, Journal of the American Academy of Dermatology.
[103] P S Cohen,et al. Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945-1977. , 1980, Progress in cardiovascular diseases.
[104] R. Craven,et al. Flagellar preparations from Pseudomonas aeruginosa: isolation and characterization , 1982, Infection and immunity.
[105] A. Prince,et al. Cross-reactivity of Pseudomonas aeruginosa antipilin monoclonal antibodies with heterogeneous strains of P. aeruginosa and Pseudomonas cepacia , 1989, Infection and Immunity.
[106] G. Pier,et al. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia , 1986, Infection and immunity.
[107] K. Irie,et al. A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide , 1991, Infection and immunity.
[108] J. G. Foster,et al. Nosocomial Pseudomonas aeruginosa urinary tract infections. , 1982, JAMA.
[109] R. J. Jones,et al. CONTROLLED TRIAL OF PSEUDOMONAS IMMUNOGLOBULIN AND VACCINE IN BURN PATIENTS , 1980, The Lancet.
[110] G. D. Vermeulen,et al. Pseudomonas aeruginosa in a center for cancer research. I. Distribution of intraspecies types from human and environmental sources. , 1972, The Journal of infectious diseases.
[111] D. Armstrong,et al. Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. , 1974, The Journal of infectious diseases.
[112] S. Cryz,et al. Protection against fatalPseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides , 1985, European Journal of Clinical Microbiology.
[113] W. Steinmüller,et al. Tolerability and immunogenicity of a polyvalent Pseudomonas aeruginosa extract vaccine in human volunteers. , 1988, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology.
[114] J. Karp,et al. Bacterial and host factors affecting Pseudomonas aeruginosa colonization versus bacteremia in granulocytopenic patients. , 1988, European journal of cancer & clinical oncology.
[115] R. Khabbaz,et al. Pseudomonas aeruginosa serotype 0:9. New cause of whirlpool-associated dermatitis. , 1983, The American journal of medicine.
[116] H. Bartsch,et al. Production of polyclonal and monoclonal antibodies for specific detection of nitrosation-proficient denitrifying bacteria in biological fluids. , 1991, Biochemical and biophysical research communications.
[117] Y. Suzuki,et al. Protective effects of S-sulfonated human gamma globulin against experimental infections in mice , 1980, Infection and immunity.
[118] J. Lagacé,et al. Four epitopes of Pseudomonas aeruginosa elastase defined by monoclonal antibodies , 1991, Infection and immunity.
[119] F. Gavini,et al. Isolation and characterization of monoclonal antibodies against alkaline phosphatase of Pseudomonas aeruginosa , 1989, Journal of clinical microbiology.
[120] Green Ne,et al. Pseudomonas infections of the foot after puncture wounds. , 1980 .
[121] R A Weinstein,et al. Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts. , 1985, The Journal of infectious diseases.
[122] J. Chia,et al. Functionally distinct monoclonal antibodies reactive with enzymatically active and binding domains of Pseudomonas aeruginosa toxin A , 1986, Infection and immunity.
[123] Y. Masuho,et al. Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa. , 1987, Journal of general microbiology.
[124] J. Wingard,et al. Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia , 1986, Antimicrobial Agents and Chemotherapy.
[125] S. Hadler,et al. An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells. , 1990, The Journal of infectious diseases.
[126] M. Pollack,et al. Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection , 1976, Infection and immunity.
[127] M. Reyes,et al. Pseudomonas endocarditis in the Detroit Medical Center. 1969-1972. , 1973, Medicine.
[128] I. Brook,et al. Bacteriology of chronic otitis media. , 1979, JAMA.
[129] H. Kaplan,et al. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[130] F. Cerra,et al. Immunotherapy of gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection. , 1986, Archives of surgery.
[131] J. Lundblad,et al. Comparative studies of impurities in intravenous immunoglobulin preparations. , 1986, Reviews of infectious diseases.
[132] J. Montgomerie,et al. Long-term Pseudomonas colonization in spinal cord injury patients. , 1980, American journal of epidemiology.
[133] A. Lerner,et al. Characteristics of nonbacteremic Pseudomonas pneumonia. , 1968, Annals of internal medicine.
[134] K. Yoshida,et al. Production and some properties of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa. , 1989, Journal of pharmacobio-dynamics.
[135] D. Levine,et al. Bacteremia in narcotic addicts at the Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study. , 1986, Reviews of infectious diseases.
[136] A. Baltch,et al. Pseudomonas aeruginosa bacteremia: a clinical study of 75 patients , 1977, The American journal of the medical sciences.
[137] M. Stanley. Bacillus pyocyaneus infections , 1947 .
[138] K. Irie,et al. N-acetyl-L-galactosaminuronic acid as an epitope common to the O-polysaccharides of Pseudomonas aeruginosa serotype A and H (Homma) recognized by a protective human monoclonal antibody. , 1990, European journal of biochemistry.
[139] J. Whitecar,et al. Pseudomonas Bacteremia in Patients with Malignant Diseases , 1970, The American journal of the medical sciences.
[140] T. Calandra,et al. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. , 1991, The Journal of infectious diseases.
[141] Henry Levison,et al. HIGH-DOSE VERSUS LOW-DOSE INTRAVENOUS IMMUNOGLOBULIN IN HYPOGAMMAGLOBULINAEMIA AND CHRONIC LUNG DISEASE , 1987, The Lancet.
[142] R. Wilson,et al. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. , 1986, The Journal of infectious diseases.
[143] J. McClain,et al. Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa. , 1989, The Journal of infectious diseases.
[144] R. Simmons,et al. Nosocomial gram-negative bacillary parotitis. , 1984, JAMA.
[145] Y. Masuho,et al. Protection against experimental Pseudomonas infection with O antigen-specific human monoclonal antibodies. , 1989, Antibiotics and chemotherapy.
[146] H. Chapel,et al. Mechanisms of infection in chronic lymphocytic leukemia. , 1987, Seminars in hematology.
[147] J. Jacobson,et al. Pseudomonas aeruginosa rash associated with a whirlpool. , 1976, JAMA.
[148] R. Hancock,et al. Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection. , 1988, Investigative ophthalmology & visual science.
[149] G. Barclay,et al. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine. , 1986, Journal of medical microbiology.
[150] J. Alexander,et al. A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients. , 1989, Burns : journal of the International Society for Burn Injuries.
[151] M. McPherson,et al. The biochemical defect in cystic fibrosis. , 1988, Clinical science.
[152] C. Kunin. A ten-year study of bacteriuria in schoolgirls: final report of bacteriologic, urologic, and epidemiologic findings. , 1970, The Journal of infectious diseases.
[153] G. Cooper,et al. Polymicrobial bacteremia in the late 1980s: predictors of outcome and review of the literature. , 1990, Medicine.
[154] M. Patzakis,et al. Septic arthritis due to pseudomonas in heroin addicts. , 1975, The Journal of bone and joint surgery. American volume.
[155] H. Hill,et al. Protective and opsonic activities of a native, pH 4.25 intravenous immunoglobulin G preparation against common bacterial pathogens. , 1986, Reviews of infectious diseases.
[156] M. Grossman,et al. Subcutaneous nodules in Pseudomonas sepsis. , 1986, The American journal of medicine.
[157] K. Irie,et al. Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa , 1991, Infection and immunity.
[158] M. Collins,et al. Immunoglobulin G: potentiation of tobramycin and azlocillin in the treatment of Pseudomonas aeruginosa sepsis in neutropenic mice and neutralization of exotoxin A in vivo. , 1986, Reviews of infectious diseases.
[159] D. Armstrong,et al. Pseudomonas aeruginosa bacteremia in patients with neoplastic disease , 1972, Cancer.
[160] M. Collins,et al. Activity of anti-lipopolysaccharide human IgM monoclonal antibodies in the treatment of Pseudomonas aeruginosa-Staphylococcus aureus polymicrobic cellulitis , 1989 .
[161] L. S. Young,et al. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. , 1983, The Journal of clinical investigation.
[162] J. Sugar,et al. Pseudomonas corneal ulcer with extended-wear soft contact lenses for myopia. , 1983, Archives of ophthalmology.